Hydrochlorothiazide (HCTZ)
Thiazide diuretic for hypertension and edema. Inhibits sodium-chloride cotransporter in the distal convoluted tubule. Not metabolized; excreted unchanged renally (~61% within 24h). Onset within 2 hours, duration up to 24 hours.
Projected serum levels — 25 mg, once daily
Maintenance schedule: 25 mg once daily (oral).
Loading schedule: 31.2 mg on day 1, then 25 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~1 days: peak ≈ 17.1 mg, trough ≈ 4.0 mg body load. Population-based estimate over 15 days for a 25 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Diuretic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 10 h
- Common dose
- 25 mg
- Suggested maximum
- 50 mg/day
- Reference dose range
- 12.5–50 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 50 mg oral — Cmax 0.37 mg/L at 2.5 h
Documented interactions
-
warning
Lithium Orotate (Microdose) + Hydrochlorothiazide (HCTZ)
Thiazide diuretic reduces lithium renal clearance, increasing plasma lithium and toxicity risk.
-
caution
Aspirin (Acetylsalicylic Acid) + Hydrochlorothiazide (HCTZ)
NSAID may reduce thiazide efficacy via prostaglandin inhibition.
-
watch
Chlorthalidone + Hydrochlorothiazide (HCTZ)
Chlorthalidone and Hydrochlorothiazide (HCTZ) both push the carbonic anhydrase in the same direction.
Serum checks 3 modeled interaction pairings for hydrochlorothiazide (hctz) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT)
Largest hypertension trial (33,357 patients) established thiazide-type diuretics as first-line therapy, with chlorthalidone performing as well or better than amlodipine and lisinopril for cardiovascular outcomes.
-
Pharmacokinetics of hydrochlorothiazide in man
Foundational pharmacokinetic study establishing HCTZ bioavailability of 60-70%, elimination half-life of 6-15 hours, and renal excretion of unchanged drug as the primary elimination route.
-
Hydrochlorothiazide vs chlorthalidone, pharmacokinetic and pharmacodynamic differences
Critical comparison revealing pharmacokinetic differences between HCTZ (t1/2 ~9h) and chlorthalidone (t1/2 ~45h), suggesting chlorthalidone provides more sustained blood pressure reduction.
3 published studies referenced in the app, each with a plain-language summary.